Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 337 companies set new 52-week lows.
HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $21 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $21 price target.
Kezar Life Sciences Presents Complete Results From The MISSION Phase 2 Trial Evaluating Zetomipzomib In Lupus Nephritis At ASN’s Kidney Week 2022 Annual Meeting
Zetomipzomib added to stable background therapy reduced proteinuria by 50% or greater (ORR) in 11 of 17 patients (64.7%) reaching end of treatment at Week 25. This benefit occurred with a 53% mean